Neuroscience — Reportable segment operating profit
Medtronic Neuroscience — Reportable segment operating profit decreased by 0.4% to $737.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 30.5%, from $1.06B to $737.00M. Over 4 years (FY 2021 to FY 2025), Neuroscience — Reportable segment operating profit shows a downward trend with a -6.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates improved operational efficiency or higher margins within the neuroscience product portfolio, while a decrease suggests rising costs or pricing pressure.
Detailed definition
This represents the operating income generated by the Neuroscience business segment after deducting direct operating exp...
Peer comparison
Comparable to segment-level operating income reported by diversified medical device peers like Abbott or Boston Scientific.
mdt_segment_neuroscience_reportable_segment_operating_profitHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $989.00M | $962.00M | $887.00M | $903.00M | $788.00M | $815.00M | $876.00M | $897.00M | $961.00M | $929.00M | $929.00M | $994.00M | $991.00M | $961.00M | $1.02B | $1.06B | $384.00M | $705.00M | $740.00M | $737.00M |
| QoQ Change | — | -2.7% | -7.8% | +1.8% | -12.7% | +3.4% | +7.5% | +2.4% | +7.1% | -3.3% | +0.0% | +7.0% | -0.3% | -3.0% | +6.6% | +3.6% | -63.8% | +83.6% | +5.0% | -0.4% |
| YoY Change | — | — | — | — | -20.3% | -15.3% | -1.2% | -0.7% | +22.0% | +14.0% | +6.1% | +10.8% | +3.1% | +3.4% | +10.2% | +6.7% | -61.3% | -26.6% | -27.7% | -30.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Medtronic's neuroscience — reportable segment operating profit?
- Medtronic (MDT) reported neuroscience — reportable segment operating profit of $737.00M in Q1 2026.
- How has Medtronic's neuroscience — reportable segment operating profit changed year-over-year?
- Medtronic's neuroscience — reportable segment operating profit decreased by 30.5% year-over-year, from $1.06B to $737.00M.
- What is the long-term trend for Medtronic's neuroscience — reportable segment operating profit?
- Over 4 years (2021 to 2025), Medtronic's neuroscience — reportable segment operating profit has grown at a -6.0% compound annual growth rate (CAGR), from $3.70B to $2.89B.
- What does neuroscience — reportable segment operating profit mean?
- The profit earned by the Neuroscience business unit from its core operations.